A new Targeted Therapeutics card on the Interventions page covers GLP-1 receptor agonists (semaglutide, tirzepatide). The Learn article on the limitations of aging clocks gains a paragraph on the aging-clock readouts that drug developers reported from their own trials in 2026, with sources. Vadim Gladyshev's commercial-ties line on Scientific Voices was rechecked. Updated 13 October 2026: it now names his long-time research partnership with Insilico Medicine rather than individual co-authored papers.
In September and October 2026, Novo Nordisk posted a preprint reporting lower protein-based organ-age estimates on semaglutide across five placebo-controlled trials (10,052 participants), Eli Lilly presented an unpublished single-arm epigenetic-clock pilot on tirzepatide, and Insilico Medicine researchers, with academic co-authors, published a peer-reviewed analysis of six proteomic clocks in 42 patients from a 71-patient lung-fibrosis drug trial. Readers meeting "organ age" headlines found nothing on the site. Analysts read the available sources (for Lilly's data only a trade-press report exists) and a separate reviewer checked the claims.
The card separates two endpoints: semaglutide's established cardiovascular and kidney benefits in high-risk trial populations, and any benefit for human aging, rated Emerging because the clock evidence comes from a company-funded preprint and an unpublished pilot, with no independent replication. No clock study included healthy, normal-weight people, and none showed added healthy years. Nothing here is a treatment recommendation.
Affected entities
Primary
Secondary
Citations
- Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials — Research Square (2026)DOI: 10.21203/rs.3.rs-11082091/v1— Organ-age estimates on semaglutide versus placebo across five trials; exploratory mediation by weight, HbA1c and CRP.
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment — Nature Biotechnology (2026)DOI: 10.1038/s41587-026-03286-y— Six proteomic clocks in the rentosertib phase 2a trial; the authors' statement that disease and aging effects cannot be separated.